Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(03): 130-135
DOI: 10.1055/s-0041-1723104
Original Article: Breast Cancer

Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India

Suresh Rao
1   Department of Radiation Oncology, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Krishna Prasad
2   Department of Medical Oncology, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Soniya Abraham
3   Research Unit, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Thomas George
3   Research Unit, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Supreeth Kakkaje Chandran
3   Research Unit, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Manjeshwar Shrinath Baliga
3   Research Unit, Mangalore Institute of Oncology, Mangalore, Karnataka, India
› Author Affiliations Funding Nil.
› Further Information
   Permissions and Reprints

Abstract

Purpose Development of cancer chemotherapy treatment-induced hyperglycemia/ diabetes (secondary diabetes) is a major problem and has never been reported from India. The present study was planned to ascertain this in women undergoing curative chemotherapy for their breast cancer.

Materials and Methods This was a retrospective chart-based study and was conducted in a cancer specialty hospital. The information on women who were nondiabetic at the start of the treatment was collected from the files. Details on cancer diagnosis, domicile, body mass index (BMI), type of diet, marital status, number of children, and previous history of diabetes if any were considered. The blood glucose levels before surgery and after the completion of radiotherapy were considered. World Health Organization (WHO) guidelines for diabetes were considered. The data were subjected to frequency and percentage and analyzed using Chi-square test. Association between the demographic details and development of Hyperglycemia or secondary diabetes or prediabetes was done using the Pearson’s correlation analysis. p < 0.05 was considered as statistically significant.

Results A total of 474 cases were included in accordance with the inclusion criteria. The results indicated that by the end of the radiation treatment, 24.89% were prediabetic, 10.97% were diabetic after being in prediabetic stage, 8.22% became diabetic without going through a prediabetic stage, and that 55.91% did not develop either prediabetic or diabetic condition. Analysis of development of secondary diabetes and prediabetes with BMI (p < 0.0001) and age (p < 0.024) showed a strong correlation and was significant.

Conclusion To the best of the authors’ knowledge, this is the first study from India, and the results indicate that the development of secondary diabetes in women undergoing curative chemotherapy is high. Attempts are underway to ascertain the cause for the development and how it can be mitigated.

Keywords

breast cancer - chemotherapy - secondary diabetes


Publication History

Article published online:
19 March 2021

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
    CrossrefPubMedGoogle Scholar
  • 2 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
    CrossrefPubMedGoogle Scholar
  • 3 World Health Organization. Guidelines for Management of Breast Cancer. EMRO Technical Publications Series 31. Geneva, Switzerland: World Health Organization 2006
  • 4 Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 2012; 20 (03) 256-267
    CrossrefPubMedGoogle Scholar
  • 5 Jeong Y, Han HS, Lee HD. et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat 2016; 48 (04) 1429-1437
    CrossrefPubMedGoogle Scholar
  • 6 Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab (Seoul) 2017; 32 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 7 Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EG, Jalving M. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev 2015; 41 (04) 376-384
    CrossrefPubMedGoogle Scholar
  • 8 Vidler J, Rogers C, Yallop D. et al. Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. J Clin Transl Endocrinol 2017; 9: 18-20
    PubMedGoogle Scholar
  • 9 Healy SJ, Nagaraja HN, Alwan D, Dungan KM. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine 2017; 56 (01) 90-97
    CrossrefPubMedGoogle Scholar
  • 10 Weiser MA, Cabanillas ME, Konopleva M. et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100 (06) 1179-1185
    CrossrefPubMedGoogle Scholar
  • 11 Hickish T, Astras G, Thomas P. et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst 2009; 101 (07) 537
    CrossrefPubMedGoogle Scholar
  • 12 Agnoli C, Berrino F, Abagnato CA. et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010; 20 (01) 41-48
    CrossrefPubMedGoogle Scholar
  • 13 Lu LJ, Wang RJ, Ran L. et al. On the status and comparison of glucose intolerance in female breast cancer patients at initial diagnosis and during chemotherapy through an oral glucose tolerance test. PLoS One 2014; 9 (04) e93630
    CrossrefPubMedGoogle Scholar
  • 14 Juanjuan L, Wen W, Zhongfen L. et al. Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study. Tumour Biol 2015; 36 (09) 6939-6947
    CrossrefPubMedGoogle Scholar
  • 15 Dieli-Conwright CM, Wong L, Waliany S, Bernstein L, Salehian B, Mortimer JE. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 2016; 122 (17) 2646-2653
    CrossrefPubMedGoogle Scholar
  • 16 Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am 2014; 43 (01) 75-102
    CrossrefPubMedGoogle Scholar
  • 17 Brady VJ, Grimes D, Armstrong T, LoBiondo-Wood G. Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. Oncol Nurs Forum 2014; 41 (06) E355-E365
    CrossrefPubMedGoogle Scholar
  • 18 Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: An important but overlooked problem. Endocrinol Metab (Seoul) 2017; 32 (02) 180-189
    CrossrefPubMedGoogle Scholar
  • 19 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15 (07) 539-553
    CrossrefPubMedGoogle Scholar
  • 20 Khatib OM, ed. Guidelines for the Prevention, Management and Care of Diabetes Mellitus. World Health Organization. Available at: http://applicationsemrowhoint/dsaf/dsa664pdf. Accessed November 20, 2020
  • 21 Diabetes Atlas IDF, Across the Globe. 7th ed. Available at:Accessed November 20, 2020
  • 22 International Diabetes Federation. The International Federation (IDF) Diabetes Atlas. 7th ed. Available at: http://www.diabetesatlas.org/. Accessed November 20, 2020
  • 23 Lipscombe LL, Chan WW, Yun L, Austin PC, Anderson GM, Rochon PA. Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 2013; 56 (03) 476-483
    CrossrefPubMedGoogle Scholar
  • 24 Gironés R, Torregrosa D, Díaz-Beveridge R. Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol 2010; 73 (03) 236-245
    CrossrefPubMedGoogle Scholar
  • 25 Padmanabha UR, Nalam U, Badiger S, Nagarajaiah P. Prevalence and risk factors of type 2 diabetes mellitus in the rural population of Mangalore, South India. Natl J Community Med 2017; 8: 456-461
    Google Scholar
  • 26 Rao CR, Kamath VG, Shetty A, Kamath A. A study on the prevalence of type 2 diabetes in coastal Karnataka. Int J Diabetes Dev Ctries 2010; 30 (02) 80-85
    CrossrefPubMedGoogle Scholar
  • 27 Dasappa H, Fathima FN, Prabhakar R, Sarin S. Prevalence of diabetes and pre-diabetes and assessments of their risk factors in urban slums of Bangalore. J Family Med Prim Care 2015; 4 (03) 399-404
    CrossrefPubMedGoogle Scholar
  • 28 Awasthi A, Rao CR, Hegde DS, Rao N K. Association between type 2 diabetes mellitus and anthropometric measurements - a case control study in South India. J Prev Med Hyg 2017; 58 (01) E56-E62
    PubMedGoogle Scholar
  • 29 Mohan V, Deepa M, Farooq S, Narayan KM, Datta M, Deepa R. Anthropometric cut points for identification of cardiometabolic risk factors in an urban Asian Indian population. Metabolism 2007; 56 (07) 961-968
    CrossrefPubMedGoogle Scholar
  • 30 Anjana RM, Deepa M, Pradeepa R. et al; ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol 2017; 5 (08) 585-596
    CrossrefPubMedGoogle Scholar